COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES

Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, De Tilleghem LBC, Cappoen N, Chaudhuri M, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Value in Health Wiley-Blackwell: No OnlineOpen / Elsevier

Publisher: ELSEVIER SCIENCE INC

City/Town: NEW YORK

Pages Range: S365-S365

Conference Proceedings Title: VALUE IN HEALTH

DOI: 10.1016/j.jval.2022.04.408

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) Analysis Group US United States (USA) (US) Complete Health Economics Outcomes and Research Solutions (CHEORS) US United States (USA) (US) Texas Oncology US United States (USA) (US)

How to cite

APA:

Huang, M., Fasching, P., Haiderali, A., Pan, W., Gray, E., Zhou, J.,... O'Shaughnessy, J. (2022). COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES. In VALUE IN HEALTH (pp. S365-S365). NEW YORK: ELSEVIER SCIENCE INC.

MLA:

Huang, M., et al. "COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES." Proceedings of the VALUE IN HEALTH NEW YORK: ELSEVIER SCIENCE INC, 2022. S365-S365.

BibTeX: Download